Prosight Management, LP Oric Pharmaceuticals, Inc. Transaction History

Prosight Management, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$5.41 - $9.43 $5.42 Million - $9.44 Million	-1,001,539 Reduced 38.82%	1,578,263 $14.5 Million
Q3 2023 Nov 14, 2023	SELL	$6.05 - $9.28 $1.1 Million - $1.69 Million	-181,666 Reduced 6.58%	2,579,802 $15.6 Million
Q2 2023 Aug 14, 2023	BUY	$4.95 - $8.4 $6.02 Million - $10.2 Million	1,216,468 Added 78.74%	2,761,468 $21.4 Million
Q1 2023 May 12, 2023	BUY	$4.26 - $6.75 $1.55 Million - $2.46 Million	365,000 Added 30.93%	1,545,000 $8.81 Million
Q4 2022 Feb 14, 2023	BUY	$2.41 - $5.89 $587,235 - $1.44 Million	243,666 Added 26.02%	1,180,000 $6.95 Million
Q3 2022 Nov 14, 2022	BUY	$3.15 - $5.24 $2.95 Million - $4.91 Million	936,334 New	936,334 $3 Million

124

66.6M

7.8K

700

Ticker ORIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,576,700
Market Cap $323M
Description
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment r...

Get notified when there are updates to the investment portfolio of Prosight Management, LP, based on Form 13F filings with the SEC.

Stay updated on Prosight Management, LP with notifications on news.